Justin C. Moser

1.8k total citations
55 papers, 762 citations indexed

About

Justin C. Moser is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Justin C. Moser has authored 55 papers receiving a total of 762 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 13 papers in Immunology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Justin C. Moser's work include Cancer Immunotherapy and Biomarkers (22 papers), CAR-T cell therapy research (17 papers) and Immunotherapy and Immune Responses (9 papers). Justin C. Moser is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), CAR-T cell therapy research (17 papers) and Immunotherapy and Immune Responses (9 papers). Justin C. Moser collaborates with scholars based in United States, Australia and Canada. Justin C. Moser's co-authors include Aaron S. Mansfield, Roxana Dronca, MC Aubry, Susan M. Harrington, Haidong Dong, Svetomir N. Markovic, Siwen Hu‐Lieskovan, David L. Rimm, Sarah V. Colonna and Lynne T. Shuster and has published in prestigious journals such as Nature, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Justin C. Moser

48 papers receiving 747 citations

Peers

Countries citing papers authored by Justin C. Moser

Since Specialization

Citations

This map shows the geographic impact of Justin C. Moser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin C. Moser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin C. Moser more than expected).

Fields of papers citing papers by Justin C. Moser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justin C. Moser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin C. Moser. The network helps show where Justin C. Moser may publish in the future.

Co-authorship network of co-authors of Justin C. Moser

This figure shows the co-authorship network connecting the top 25 collaborators of Justin C. Moser. A scholar is included among the top collaborators of Justin C. Moser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justin C. Moser. Justin C. Moser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data 2025 ·Pharmacogenomics and Personalized Medicine ·(unknown), Christoph Meier, Carola A. Huber, Justin C. Moser, Henriette E. Meyer zu Schwabedissen, Samuel Allemann, Cornelia Schneider	0
2	Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL-3 inhibitor, in patients with advanced malignancies. 2024 ·Journal of Clinical Oncology ·Justin C. Moser, Kyriakos P. Papadopoulos, Jordi Rodón, Yaara Ofir-Rosenfeld, Josefin-Beate Holz, (unknown)	10
3	Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL). 2024 ·Journal of Clinical Oncology ·(unknown), Abdul Rafeh Naqash, Reva Schneider, Aditi Shastri, Maximilian Stahl, Justin C. Moser, (unknown), Yazan F. Madanat, Brian A. Jonas, Eytan M. Stein, Shirish M. Gadgeel, James McCloskey, Ashwin Gollerkeri, (unknown), Yogesh K. Chutake, Sagar Agarwal, Patrick Henrick, Kelvin Shi, Naval Daver	6
4	A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab. 2024 ·Journal of Clinical Oncology ·Justin C. Moser, Mateusz Opyrchal, (unknown), Brendan D. Curti, Igor Puzanov, Jeffrey A. Sosman, Mehmet Asım Bilen, Kristin Morris, Christopher J. Nirschl, (unknown), (unknown), (unknown), Kulandayan K. Subramanian, Oliver Schönborn‐Kellenberger, Sameer Chopra, Randi Isaacs	2
5	Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors. 2024 ·Journal of Clinical Oncology ·Sajeve Thomas, (unknown), Brian S. Henick, Rom S. Leidner, (unknown), (unknown), Jared Weiss, Michael E. Hurwitz, Jaspreet Singh Grewal, Jason J. Luke, Shrikanta Chattopadhyay, Yun Wang, (unknown), J. A. H. Murray, Débora Barton, (unknown), Gavin MacBeath, Justin C. Moser	0
6	Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data 2024 ·Cancer Immunology Immunotherapy ·Justin C. Moser, Shailender Bhatia, Asim Amin, Anna C. Pavlick, Keith A. Betts, Ella X. Du, (unknown), (unknown), Swetha Srinivasan, (unknown), (unknown), Maurice Lobo, Melanie Pe Benito, (unknown), Yan Chen, (unknown), Lei Yin, (unknown), Jeffrey S. Weber	1
7	Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2) 2024 ·Journal for ImmunoTherapy of Cancer ·Diwakar Davar, Ludimila Cavalcante, Nehal J. Lakhani, Justin C. Moser, (unknown), Meredith McKean, Mark Voskoboynik, Rachel E. Sanborn, Jaspreet Singh Grewal, (unknown), Amita Patnaik, Justin F. Gainor, Mario Sznol, Amanda Enstrom, (unknown), Heidi Leblanc, (unknown), Michael Chisamore, Stanford L. Peng, (unknown)	3
8	618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors 2023 ·SHILAP Revista de lepidopterología ·Justin C. Moser, Angela Alistar, Ezra E.W. Cohen, Edward G. Garmey, Syed Mohammad Ali Kazmi, (unknown), Lijun Sun, Timothy A. Yap, Devalingam Mahalingam	4
9	737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors 2023 ·SHILAP Revista de lepidopterología ·Justin C. Moser, Mateusz Opyrchal, (unknown), Mehmet Asım Bilen, Brendan D. Curti, Igor Puzanov, Kristin Morris, Christopher J. Nirschl, (unknown), (unknown), (unknown), Kulandayan K. Subramanian, Sameer Chopra, (unknown)	2
10	736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies 2023 ·SHILAP Revista de lepidopterología ·Justin C. Moser, Ryan J. Sullivan, Matthew H. Taylor, Igor Puzanov, Gerald S. Falchook, Mario Sznol, (unknown), (unknown), (unknown), (unknown), Hirdesh Uppal, Jeremy Barton, (unknown), Aaron M. Ring, Harriet M. Kluger	2
11	Abstract CT133: Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors 2023 ·Cancer Research ·(unknown), Justin C. Moser, Mateusz Opyrchal, Brendan D. Curti, Mehmet Asım Bilen, (unknown), (unknown), (unknown), Kulandayan K. Subramanian, Sameer Chopra, (unknown)	1
12	253 Cell avidity drives the functional responses of immunotherapies with superior correlates to in vivo performance 2023 ·SHILAP Revista de lepidopterología ·Jens Eberlein, Justin C. Moser, (unknown), Luis Acero, Zhong Zhou, (unknown), Keith Bailey, (unknown), Andrea Candelli	1
13	Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient 2023 ·Case Reports in Dermatology ·Max Miller, (unknown), (unknown), Justin C. Moser	4
14	The Mechanisms of Action of Tumor Treating Fields 2022 ·Cancer Research ·Justin C. Moser, Ellaine Salvador, (unknown), Kenneth D. Swanson, Jack A. Tuszyński, Kristen W. Carlson, Narasimha Kumar Karanam, Chirag B. Patel, Michael D. Story, Emil Lou, Carsten Hagemann	65
15	Uveal melanoma: laboratory advances and new frontiers in patient care 2021 ·Current Opinion in Ophthalmology ·(unknown), Justin C. Moser, Lauren A. Dalvin	2
16	Correlation of novel ALK^ATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma 2020 ·Histopathology ·Kabeer Shah, Jadee Neff, Lori A. Erickson, (unknown), Sarah M. Jenkins, Aaron S. Mansfield, Justin C. Moser, (unknown), John A. Copland, Kevin C. Halling, Thomas J. Flotte	5
17	Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011 2017 ·Cancer Medicine ·Elizabeth Ann L. Enninga, Justin C. Moser, Amy L. Weaver, Svetomir N. Markovic, Jerry D. Brewer, Alexey A. Leontovich, Tina J. Hieken, Lynne T. Shuster, Lisa A. Kottschade, (unknown), Aaron S. Mansfield, Roxana Dronca	101
18	c-Met expression and MET amplification in malignant pleural mesothelioma 2016 ·Annals of Diagnostic Pathology ·Melanie C. Bois, Aaron S. Mansfield, William R. Sukov, Sarah M. Jenkins, Justin C. Moser, Christopher A. Sattler, Carin Y. Smith, Julian R. Molina, Tobias Peikert, Anja C. Roden	15
19	Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma 2015 ·PLoS ONE ·Sara Valpione, Justin C. Moser, Raffaele Parrozzani, (unknown), Aaron S. Mansfield, Simone Mocellin, Jacopo Pigozzo, Edoardo Midena, Svetomir N. Markovic, Camillo Aliberti, L Campana, Vanna Chiarion‐Sileni	31
20	The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma 2014 ·Melanoma Research ·Justin C. Moser, José S. Pulido, Roxana Dronca, Robert R. McWilliams, Svetomir N. Markovic, Aaron S. Mansfield	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact